Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: Can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?

Roberto M. Lemoli, Alessandra D'Addio

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The majority of patients with acute myeloid leukemia (AML) achieve complete remission (CR) after induction/consolidation chemotherapy. The optimal post-remission treatment is still a matter of debate. However, the intensification of post-remission treatment, including high-dose chemotherapy followed by infusion of autologous or allogeneic stem cells, has progressively increased, considering the high risk of relapse without any further post-remission therapy. The most effective conditioning regimen before hematopoietic stem cell transplantation (HSCT) remains controversial. The combination of busulfan and cyclophosphamide (BU-Cy) is the most used conditioning treatment as its anti-leukemic activity is well established.

Original languageEnglish
Pages (from-to)172
Number of pages1
JournalRevista Brasileira de Hematologia e Hemoterapia
Volume33
Issue number3
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Transplantation Conditioning
Busulfan
Melphalan
Autologous Transplantation
Hematopoietic Stem Cell Transplantation
Homologous Transplantation
Leukemia
Consolidation Chemotherapy
Remission Induction
Induction Chemotherapy
Therapeutics
Acute Myeloid Leukemia
Cyclophosphamide
Stem Cells
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

@article{087f630111024ba5ad317a34c9bf62e5,
title = "Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: Can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?",
abstract = "The majority of patients with acute myeloid leukemia (AML) achieve complete remission (CR) after induction/consolidation chemotherapy. The optimal post-remission treatment is still a matter of debate. However, the intensification of post-remission treatment, including high-dose chemotherapy followed by infusion of autologous or allogeneic stem cells, has progressively increased, considering the high risk of relapse without any further post-remission therapy. The most effective conditioning regimen before hematopoietic stem cell transplantation (HSCT) remains controversial. The combination of busulfan and cyclophosphamide (BU-Cy) is the most used conditioning treatment as its anti-leukemic activity is well established.",
author = "Lemoli, {Roberto M.} and Alessandra D'Addio",
year = "2011",
month = "6",
doi = "10.5581/1516-8484.20110044",
language = "English",
volume = "33",
pages = "172",
journal = "Revista Brasileira de Hematologia e Hemoterapia",
issn = "1516-8484",
publisher = "Sociedade Brasileira de Hematologia e Hemoterapia",
number = "3",

}

TY - JOUR

T1 - Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation

T2 - Can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?

AU - Lemoli, Roberto M.

AU - D'Addio, Alessandra

PY - 2011/6

Y1 - 2011/6

N2 - The majority of patients with acute myeloid leukemia (AML) achieve complete remission (CR) after induction/consolidation chemotherapy. The optimal post-remission treatment is still a matter of debate. However, the intensification of post-remission treatment, including high-dose chemotherapy followed by infusion of autologous or allogeneic stem cells, has progressively increased, considering the high risk of relapse without any further post-remission therapy. The most effective conditioning regimen before hematopoietic stem cell transplantation (HSCT) remains controversial. The combination of busulfan and cyclophosphamide (BU-Cy) is the most used conditioning treatment as its anti-leukemic activity is well established.

AB - The majority of patients with acute myeloid leukemia (AML) achieve complete remission (CR) after induction/consolidation chemotherapy. The optimal post-remission treatment is still a matter of debate. However, the intensification of post-remission treatment, including high-dose chemotherapy followed by infusion of autologous or allogeneic stem cells, has progressively increased, considering the high risk of relapse without any further post-remission therapy. The most effective conditioning regimen before hematopoietic stem cell transplantation (HSCT) remains controversial. The combination of busulfan and cyclophosphamide (BU-Cy) is the most used conditioning treatment as its anti-leukemic activity is well established.

UR - http://www.scopus.com/inward/record.url?scp=80051621488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051621488&partnerID=8YFLogxK

U2 - 10.5581/1516-8484.20110044

DO - 10.5581/1516-8484.20110044

M3 - Article

C2 - 23049286

AN - SCOPUS:80051621488

VL - 33

SP - 172

JO - Revista Brasileira de Hematologia e Hemoterapia

JF - Revista Brasileira de Hematologia e Hemoterapia

SN - 1516-8484

IS - 3

ER -